Moderna (MRNA) 8-K Current Report — March 5, 2026
Filed: March 5, 2026
Health Care
Biological Products, (No Diagnostic Substances)Moderna (MRNA) 8-K current report filed with SEC EDGAR on March 5, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 1.01: Entry into a Material Definitive Agreement
Moderna 8-K Mar 5, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Moderna settles all global LNP patent litigation with Arbutus/Genevant for a mandatory $950M lump sum due by July 8, 2026
- • Additional $1.3B contingent payment triggered if Federal Circuit rejects Moderna's §1498 defense; worst-case total exposure = $2.25B
Get deeper insights on Moderna
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.